{"entity":{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","aka":[],"tldr":"Paediatric oncologist whose trials established transplant and 13-cis-retinoic acid for high-risk neuroblastoma.","summary":"Katherine Matthay is Professor Emerita of Pediatrics at UCSF, within the UCSF Helen Diller Family Comprehensive Cancer Center, and a neuroblastoma investigator with the Children's Oncology Group (COG). A paediatric oncologist and long-time chair of COG neuroblastoma studies, she led the CCG-3891 trial establishing myeloablative therapy and 13-cis-retinoic acid in high-risk neuroblastoma and pioneered 131I-MIBG therapy for relapsed disease. Her papers report the Children's Cancer Group trial of intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid, and the long-term results of that randomised trial. Her work links iobenguane I-131 and radioligand therapy to paediatric neuroblastoma.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Katherine%20K.%20Matthay"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matthay%20KK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Katherine%20K.%20Matthay"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":["radioligand-therapy"],"targets":[],"drugs":["i131-mibg"],"companies":["childrens-oncology-group"],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor Emerita of Pediatrics, UCSF; Children's Oncology Group neuroblastoma investigator","institutionId":"ucsf","specialisms":["Paediatric oncology","Neuroblastoma","MIBG therapy"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Katherine%20K.%20Matthay"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matthay%20KK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Katherine%20K.%20Matthay"}],"papers":[{"title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group","journal":"New England Journal of Medicine","year":1999,"url":"https://doi.org/10.1056/NEJM199910143411601","doi":"10.1056/NEJM199910143411601"},{"title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study","journal":"Journal of Clinical Oncology","year":2009,"url":"https://doi.org/10.1200/JCO.2007.13.8925","doi":"10.1200/JCO.2007.13.8925"}]},"route":"/people/katherine-matthay/","neighbours":{"cancer":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"drug":[{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/"}],"company":[{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}